mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2020-11-1-6-13mvjr-1036Research ArticleОБЗОРЫREVIEWПРИМЕНЕНИЕ АНТИПСИХОТИКОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ ПРИ ШИЗОФРЕНИИAPPLICATION OF ANTIPSYCHOTICS OF LONG-TERM ACTION IN SCHIZOPHRENIAhttps://orcid.org/0000-0002-2743-3223БибековаЖ. Б.BibekovaZh. B.

Жазира Бектурсыновна Бибекова — ассистент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии.

Караганда

Zhazira B. Bibekova — assistant of Neurology, neurosurgery, psychiatry and rehabilitology department.

Karaganda

zhaz88@bk.ruhttps://orcid.org/0000-0002-5129-0402СтрельцовЕ. А.Strel’covE. A.

Евгений Александрович Стрельцов — врач-резидент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии.

Караганда

Evgeny A. Strel’tsov — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department.

Karaganda 

lidigi@mail.ruhttps://orcid.org/0000-0001-8077-365XМакарчукА. С.MakarchukA. S.

 Антон Сергеевич Макарчук — врач-резидент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии.

Караганда

Anton S. Makarchuk — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department.

Karaganda

Anton95-boss@mail.ruМедицинский университет КарагандыКазахстанKaraganda Medical UniversityKazakhstan202030032020111613Copyright © Бибекова Ж.Б., Стрельцов Е.А., Макарчук А.С., 20202020Бибекова Ж.Б., Стрельцов Е.А., Макарчук А.С.Bibekova Z.B., Strel’cov E.A., Makarchuk A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1036

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии антипсихотиками длительного действия при шизофрении. Подробно освещены результаты рандомизированных исследований последних лет. Рассмотрена эффективность приема препаратов согласно шкалам общего клинического впечатления тяжести состояния (CGI-S), общего клинического впечатления изменения состояния в процессе терапии (CGI-I) и позитивных и негативных синдромов (PANSS). Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и другим.

This literature review addresses the effectiveness and safety of long-acting antipsychotic therapy for schizophrenia. The results of randomized trials of recent years are described in detail. The efficacy of taking drugs at the following key research points was examined: the general clinical impression of the severity of the condition (CGI-S), the general clinical impression of the change in state during treatment (CGI-I), and the positive and negative syndrome scale (PANSS). A systematic literature search was conducted using the Scopus, Web of Science, MedLine, elibrary, and other databases.

шизофрениягалоперидол деканоатрисперидонпалиперидон пальмитатарипипразол лауроксилобзорschizophreniahaloperidol decanoaterisperidonepaliperidone palmitatearipiprazole lauroxylreviewReferencesKaram C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. // Trends Pharmacol Sci. – 2010. – V.31(8). – P.381–90. doi: 10.1016/j.tips.2010.05.004Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci. 2010;31(8):381– 90. doi: 10.1016/j.tips.2010.05.004Xu Y., Ren J., Ye H. Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A metaanalysis. // Gene. – 2018. – V.651. – P.94–99. doi: 10.1016/j. gene.2018.01.069.Xu Y, Ren J, Ye H. Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. Gene. 2018;651:94–99. doi: 10.1016/j. gene.2018.01.069.National Institute of Mental Health Schizophrenia. Available online: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. (accessed on 1 February 2016)National Institute of Mental Health Schizophrenia. Available online: https://www.nimh.nih.gov/health/topics/ schizophrenia/index.shtml. (accessed on 1 February 2016)Zhong X., Shi H., Hou L., Chen B., Peng Q., et al. Neuropsychiatric features of Neurosyphilis: frequency, relationship with the severity of cognitive impairment and comparison with Alzheimer disease. // Dement Geriatr Cogn Disord. – 2017. – V.43(5–6). – P.308–319. doi: 10.1159/000476060.Zhong X, Shi H, Hou L, Chen B, Peng Q, et al. Neuropsychiatric features of Neurosyphilis: frequency, relationship with the severity of cognitive impairment and comparison with Alzheimer disease. Dement Geriatr Cogn Disord. 2017;43(5– 6):308–319. doi: 10.1159/000476060.Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. // Lancet. – 2016. – V.388(10039). – P.86–97. doi: 10.1016/S01406736(15)01121-6Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97. doi: 10.1016/S0140-6736(15)01121- 6Laursen T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. // Schizophr Res. – 2011. –Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131(1–3):101–4. doi: 10.1016/j.schres.2011.06.008V.131(1–3). – P.101–4. doi: 10.1016/j.schres.2011.06.008Leng CH, Chou MH, Lin SH, Yang YK, Wang JD. Estimation of life expectancy, loss-of-life expectancy, and lifetime health- care expenditures for schizophrenia in Taiwan. Schizophr Res. 2016;171(1–3):97–102. doi: 10.1016/j.schres.2016.01.033Leng C.H., Chou M.H., Lin S.H., Yang Y.K., Wang J.D. Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan. // Schizophr Res. – 2016. – V.171(1–3). – P.97–102. doi: 10.1016/j.schres.2016.01.033Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Pre- mature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81. doi: 10.1001/jamapsychiatry.2015.1737Olfson M., Gerhard T., Huang C., Crystal S., Stroup T.S. Premature Mortality Among Adults With Schizophrenia in the United States. // JAMA Psychiatry. – 2015. – V.72(12). – P.1172–81. doi: 10.1001/jamapsychiatry.2015.1737Walker ER, McGee RE, Druss BG. Mortality in mental dis- orders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334- 41. doi: 10.1001/jamapsychiatry.2014.2502Walker E.R., McGee R.E., Druss B.G. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. // JAMA Psychiatry. - 2015. – V.72(4). – P.334–41. doi: 10.1001/jamapsychiatry.2014.2502GBD 2016 Disease and Injury Incidence and Prevalence Col- laborators.. Global, regional, and national incidence, preva- lence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017;390 (10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. // Lancet. -Robertson L. Mental Health Matters. Volume 4. Health Ser- vice; Gauteng, South Africa; 2017.– V.390(10100). – P.1211–1259. doi: 10.1016/S01406736(17)32154-2. 11. Robertson L. Mental Health Matters. Volume 4. - Health Service; Gauteng, South Africa; 2017.Stringer J.L. Antipsychotics or Neuroleptics. In: Stringer J.L., ed. Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 5th ed. McGraw-Hill; New York, NY, USA: Available at: http://accessmedicine.mhmedical.com/ content.aspx?bookid=2147&sectionid=161351718. [accessed on 7 March 2019].Stringer J.L. Antipsychotics or Neuroleptics. In: Stringer J.L., ed. Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 5th ed. McGraw-Hill; New York, NY, USA: Available at: http://accessmedicine.mhmedical.com/ content.aspx?bookid=2147&sectionid=161351718. [accessed on 7 March 2019].Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. doi: 10.4088/jcp.v63n1007Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. // J Clin Psychiatry. – 2002. – V.63(10). – P.892–909. doi: 10.4088/jcp.v63n1007Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2. doi: 10.1186/1471-244X-10-2.Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. // BMC Psychiatry. -2010. – V.10. – P.2. doi: 10.1186/1471-244X-10-2.Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real- world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183- 198. doi: 10.2147/NDT.S189245.Di Lorenzo R., Ferri P., Cameli M., Rovesti S., Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a realworld clinical setting. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.183-198. doi: 10.2147/NDT.S189245.Gabriel R, Wojtanowicz T, Farokhpay R, Bota R. Acute transaminitis after initial days of starting haloperidol. Ment Illn. 2019;11(1):8113. doi: 10.4081/mi.2019.8113.Gabriel R., Wojtanowicz T., Farokhpay R., Bota R. Acute transaminitis after initial days of starting haloperidol. // Ment Illn. – 2019. – V.11(1). – P.8113. doi: 10.4081/mi.2019.8113.European Medicines Agency. Haldol Decanoate and Associated Names: Assessment Report. 2017. Committee for Medicinal Products for Human Use (CHMP).) (EMA/217985/2017). Available at: http://www.ema.europa.eu [accessed on 7 March 2019].European Medicines Agency. Haldol Decanoate and Associated Names: Assessment Report. 2017. Committee for Medicinal Products for Human Use (CHMP).) (EMA/217985/2017). Available at: http://www.ema.europa.eu [accessed on 7 March 2019].Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study. Eur Psychiatry. 2016;37:43–48. doi: 10.1016/j.eurpsy.2016.04.009Taylor D.M., Sparshatt A., O’Hagan M., Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study. // Eur Psychiatry. – 2016. – V.37. – P.43–48. doi: 10.1016/j.eurpsy.2016.04.009McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA et all. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978-87. doi: 10.1001/jama.2014.4310.McEvoy J.P., Byerly M., Hamer R.M., Dominik R., Swartz M.S., et all. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. // JAMA. – 2014. – V.311(19). – P.1978-87. doi: 10.1001/jama.2014.4310.Mace S, Dzahini O, O’Hagan M, Taylor D. Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study. Ther Adv Psychopharmacol. 2018;8(9):241-249. doi: 10.1177/2045125318767587Mace S., Dzahini O., O’Hagan M., Taylor D. Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study. // Ther Adv Psychopharmacol. – 2018. –V.8(9). – P.241-249. doi: 10.1177/2045125318767587Hori H, Katsuki A, Atake K, Yoshimura R. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. Front Psychiatry. 2018;9:74. doi: 10.3389/fpsyt.2018.00074Hori H., Katsuki A., Atake K., Yoshimura R. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. // Front Psychiatry. – 2018. – V.9. – P.74. doi: 10.3389/fpsyt.2018.00074.Mihaljevic-Peles A, Sagud M, Filipcic IS, Grosic V, Pedisic I, Emsley R. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatr Danub. 2016;28(3):263-272. PMID: 27658835Mihaljevic-Peles A., Sagud M., Filipcic I.S., Grosic V., Pedisic I., Emsley R. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. // Psychiatr Danub. – 2016. – V.28(3). – P.263-272. PMID: 27658835 23. Giraud-Baro E., Dassa D., De Vathaire F., Garay R.P., Obeid J. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). // BMC Psychiatry. – 2016. – V.16. – P.8. doi: 10.1186/s12888-0160712-1.Giraud-Baro E, Dassa D, De Vathaire F, Garay RP, Obeid J. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). BMC Psychiatry. 2016;16:8. doi: 10.1186/s12888-016-0712-1.Jang S., Woo J. Five month-persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report. // Clinical Psychopharmacology and Neuroscience. – 2017. – V.15(3). – P.288–291. doi: 10.9758/ cpn.2017.15.3.288Jang S., Woo J. Five month-persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report. Clinical Psychopharmacology and Neuroscience. 2017;15(3):288–291. doi: 10.9758/ cpn.2017.15.3.288Emsley R., Parellada E., Bioque M., Herrera B., Hernando T., Garcia-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. // Int Clin Psychopharmacol. – 2018. –Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, Garcia-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018;33(1):15–33. doi:10.1097/YIC.000000000000019V.33(1). – P.15–33. doi:10.1097/YIC.000000000000019Li N, Feng Y, Lu H, Cai SL, Zhuo J, et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat. 2018;14:825-837. doi: 10.2147/NDT.S158353Li N., Feng Y., Lu H., Cai S.L., Zhuo J., et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. // Neuropsychiatr Dis Treat. – 2018. – V.14. – P.825-837. doi: 10.2147/NDT.S158353Fernández-Miranda JJ., Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. International Clinical Psychopharmacology. 2017;32(1):6–12. doi: 10.1097/ YIC.0000000000000151Fernández-Miranda J.J., Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. // International Clinical Psychopharmacology. – 2017. - V32(1). - P6–12. doi: 10.1097/ YIC.0000000000000151Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1685-1694. doi: 10.2147/ NDT.S191803Si T., Zhuo J., Feng Y., Lu H., Hong D., Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.1685-1694. doi: 10.2147/NDT.S191803Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1365-1379. doi: 10.2147/NDT.S197225Mathews M., Gopal S., Nuamah I., Hargarter L., Savitz A.J., et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.1365-1379. doi: 10.2147/NDT.S197225Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatr Dis Treat. 2019;15:731-737. doi: 10.2147/NDT.S194264Nash A.I., Turkoz I., Savitz A.J., Mathews M., Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.731-737. doi: 10.2147/NDT.S194264Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatr Dis Treat. 2018;14:2807-2816. doi: 10.2147/ NDT.S175364Mathews M., Nuamah I., Savitz A.J., Hough D.W., Najarian D., et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. // Neuropsychiatr Dis Treat. – 2018. – V.14. – P.2807-2816. doi: 10.2147/NDT.S175364Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Resident Opinion. 2015;31(11):2043–2054. doi: 10.1185/03007995.2015.1085849Gopal S., Vermeulen A., Nandy P., Ravenstijn P., Nuamah I., et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. // Current Medical Resident Opinion. – 2015. – V.31(11). – P.2043–2054. doi: 10.1185/03007995.2015.1085849Hard ML, Wehr AY, Du Y, Weiden PJ, Walling D, von Moltke L. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. J Clin Psychopharmacol. 2018;38(5):435–441. doi: 10.1097/JCP.0000000000000921Hard M.L., Wehr A.Y., Du Y., Weiden P.J., Walling D., von Moltke L. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. // J Clin Psychopharmacol. – 2018. – V.38(5). – P.435–441. doi: 10.1097/JCP.0000000000000921McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. J Clin Psychiatry. 2017;78(8):1103-1109. doi: 10.4088/ JCP.17m11625.McEvoy J.P., Risinger R., Mykhnyak S., Du Y., Liu C.C., Stanford A.D. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. // J Clin Psychiatry. – 2017. – V.78(8). – P.1103-1109. doi: 10.4088/JCP.17m11625.Risinger R, Hard M, Weiden PJ. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Psychopharmacol Bull. 2017;47(3):26-34. PMID: 28839337Risinger R., Hard M., Weiden P.J. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. // Psychopharmacol Bull. – 2017. – V.47(3). – P.26-34. PMID: 28839337Cameron C, Zummo J, Desai DN, Drake C, Hutton B, Kotb A. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. Value Health. 2017;20(7):876-885. doi: 10.1016/j.jval.2017.03.010Cameron C., Zummo J., Desai D.N., Drake C., Hutton B., Kotb A. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. // Value Health. – 2017. – V.20(7). – P.876-885. doi: 10.1016/j.jval.2017.03.010Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395-403. doi: 10.1017/S1092852918001104Nasrallah H.A., Aquila R., Du Y., Stanford A.D., Claxton A., Weiden P.J. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. // CNS Spectr. – 2019. – V.24(4). – P.395-403. doi: 10.1017/S1092852918001104Mogwitz S, Buse J, Wolff N, Roessner V. Update on the Pharmacological Treatment of Tics with Dopamine- Modulating Agents. ACS Chem Neurosci. 2018;9(4):651-672. doi: 10.1021/acschemneuro.7b00460Mogwitz S., Buse J., Wolff N., Roessner V. Update on the Pharmacological Treatment of Tics with DopamineModulating Agents. // ACS Chem Neurosci. – 2018. – V.9(4). – P.651-672. doi: 10.1021/acschemneuro.7b00460Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, et al. Long- term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59-66. doi: 10.1192/bjpo. bp.115.002576Zhao Y.J., Lin L., Teng M., Khoo A.L., Soh L.B., et al. Longterm antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. // BJPsych Open. – 2016. – V.2(1). – P.59-66. doi: 10.1192/bjpo.bp.115.002576Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;(2):CD000307. doi: 10.1002/14651858.CD000307.pub2.Maayan N., Quraishi S.N., David A., Jayaswal A., Eisenbruch M., et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. // Cochrane Database Syst Rev. – 2015. – V.(2). – P.CD000307. doi: 10.1002/14651858.CD000307.pub2.Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;(2):CD001164. doi: 10.1002/14651858.CD001164Coutinho E., Fenton M., Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. // Cochrane Database Syst Rev. – 2000. – V.(2). – P.CD001164. doi: 10.1002/14651858.CD001164Mahapatra J, Quraishi SN, David A, Sampson S, Adams CE. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Cochrane Database Syst Rev. 2014;(6):CD001470. doi: 10.1002/14651858.CD001470.pub2.Mahapatra J., Quraishi S.N., David A., Sampson S., Adams C.E. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. // Cochrane Database Syst Rev. – 2014. – V.(6). – P.CD001470. doi: 10.1002/14651858. CD001470.pub2.Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company;2018.Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company; 2018.Fefeu M, De Maricourt P, Cachia A, Hoertel N, Vacheron MN, et al. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Res. 2018;270:205-210. doi: 10.1016/j.psychres.2018.09.041.Fefeu M, De Maricourt P, Cachia A, Hoertel N, Vacheron MN, et al. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. // Psychiatry Res. – 2018. – V.270. – P.205-210. doi: 10.1016/j.psychres.2018.09.041.Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Berg- strom RF. Olanzapine long-acting injection: a 24-week, ran- domized, double-blind trial of maintenance treatment in pa- tients with schizophrenia. Am J Psychiatry. 2010;167(2):181-9. doi: 10.1176/appi.ajp.2009.07081221.Kane J.M., Detke H.C., Naber D., Sethuraman G., Lin D.Y., Bergstrom R.F. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. // Am J Psychiatry. – 2010. – V.167(2). – P.181-9. doi: 10.1176/appi.ajp.2009.07081221.Kane J.M., Detke H.C., Naber D., Sethuraman G., Lin D.Y., Bergstrom R.F. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. // Am J Psychiatry. – 2010. – V.167(2). – P.181-9. doi: 10.1176/appi.ajp.2009.07081221.

The authors declare that there are no conflicts of interest present.